EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSACLG00000014862
Gene Symbol: KCNQ2
3 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSACLG00000023724
Gene Symbol: KCNQ3
3 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSACLG00000026094
Gene Symbol: KCNQ5
1 Cross references
200 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSACLG00000013614
Gene Symbol: KCNQ2A
1 Cross references
184 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSACLG00000000416
Gene Symbol: PSENEN
3 Cross references
185 Possible Orthologues:

Presenilin-1-Like

Ensembl ID : ENSACLG00000000313
Gene Symbol: LOC113012058
3 Cross references
202 Possible Orthologues:

Presenilin-2-Like

Ensembl ID : ENSACLG00000003436
Gene Symbol: LOC113023515
3 Cross references
206 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSACLG00000013605
Gene Symbol: LOC113014899
3 Cross references
250 Possible Orthologues:

Probable Histone Deacetylase 1-B

Ensembl ID : ENSACLG00000019646
Gene Symbol: LOC113012179
4 Cross references
257 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSACLG00000022799
Gene Symbol: PGR
3 Cross references
193 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSACLG00000013431
Gene Symbol: PTGDR2
3 Cross references
145 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSACLG00000018141
Gene Symbol: PTGDR2
4 Cross references
134 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).